[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341405-105":59,"doc-detail-341405-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","afatinib-or-bevacizumab-in-combination-with-osimertinib-efficiently-control-tumor-development-in-orthotopic-murine-models-of-non-small-lung-cancer","Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer","","Lung cancer is among the most prevalent and lethal malignancies, and preclinical models are vital for evaluating new therapies while incorporating tumor genetics. This study established luciferase-expressing cell lines across diverse genetic backgrounds typical of pulmonary adenocarcinoma and characterized them through responses to multiple drugs. The work developed orthotopic preclinical mouse models of non-small cell lung cancer with very high engraftment efficiency, enabling streamlined monitoring of tumor growth and dissemination. Combination treatment with osimertinib and bevacizumab showed beneficial effects in EGFRmutated tumors, and adding afatinib to osimertinib-treated tumors suppressed growth in escape.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/afatinib-or-bevacizumab-in-combination-with-osimertinib-efficiently-control-tumor-development-in-orthotopic-murine-models-of-non-small-lung-cancer/341405/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/afatinib-or-bevacizumab-in-combination-with-osimertinib-efficiently-control-tumor-development-in-orthotopic-murine-models-of-non-small-lung-cancer/341405.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What models were developed to study non-small cell lung cancer therapies?","Question",{"text":113,"@type":114},"The study established luciferase-expressing cell lines from genetic backgrounds typical of pulmonary adenocarcinoma and developed orthotopic preclinical mouse models of NSCLC with very high engraftment efficiency. These models enable monitoring of tumor growth and dissemination in response to treatment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did osimertinib and bevacizumab perform in EGFRmutated tumors?",{"text":118,"@type":114},"Concomitant treatment with osimertinib and bevacizumab showed a beneficial therapeutic effect on EGFRmutated tumors in the orthotopic murine models.",{"name":120,"@type":111,"acceptedAnswer":121},"What was the effect of adding afatinib to osimertinib-treated tumors in escape?",{"text":122,"@type":114},"Adding afatinib to osimertinib-treated tumors during escape led to tumor growth inhibition. Similar growth inhibition was not observed with selumetinib or simvastatin.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341405,1790273367,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","PLOS ONE  \nOPEN ACCESS  \nCitation: Jarry U, Bostoen M, Archambeau J, Pineau R, Chaillot L, Jouan F, et al. (2024) Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer. PLoSONE 19(6): e0304914 . [https://doi.org/10.1371/](https://doi.org/10.1371/)[ ](https://doi.org/10.1371/)[journal.pone.0304914](journal.pone.0304914)  \nEditor: Rama Krishna Kancha, Osmania University, Hyderabad, India, INDIA  \nReceived: May 19, 2023  \nAccepted: May 21, 2024  \nPublished: June 27, 2024  \nCopyright: © 2024 Jarry et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the article and its supporting information files.  \nFunding: This work was supported by the Agence Nationale de la Recherche (ANR) through the Labcom ONCOTRIAL 2014-2019 project (University of Rennes 1 – UMS BIOSIT– BIOTRIAL) awarded to TG, and by the “Region Bretagne” within the framework of the MOPCAP collaborative project, accompanied by “Biotech  \nRESEARCH ARTICLE  \nAfatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer  \nUlrich Jarry1,2 *, Megane Bostoen1, J´erome Archambeau1,3, Rapha¨el Pineau3, Laura Chaillot1,3, Florence Jouan3, H´elène Solhi1, Hugo Ferrari1, R´emy Le Guevel1, Valentine Mennessier2, Herv´e Lena3,4, Romain Corre3,4, Charles Ricordel3,4, Thierry Guillaudeux1,3, R´emy Pedeux1,3 *  \n1 Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France, 2 Biotrial Pharmacology, Unit´e de Pharmacologie Pr´eclinique, Rennes, France, 3 Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France, 4 Centre Hospitalier Universitaire de Rennes, Univ Rennes, Rennes, France  \n* [remy.pedeux@univ-rennes.fr](remy.pedeux@univ-rennes.fr) (RP); [ulrich.jarry@univ-rennes.fr](ulrich.jarry@univ-rennes.fr) (UJ)  \nAbstract  \nLung cancer is one of the most common and deadliest cancers. Preclinical models are essential to study new therapies and combinations taking tumor genetics into account. We have established cell lines expressing the luciferase gene from lines with varied genetic backgrounds, commonly encountered in patients with pulmonary adenocarcinoma. We have characterized these lines by testing their response to multiple drugs. Thus, we have developed orthotopic preclinical mouse models of NSCLC with very high engraftment efficiency. These models allow the easy monitoring of tumor growth, particularly in response to treatment, and of tumor cells dissemination in the body. We show that concomitant treatment with osimertinib (3rd generation tyrosine kinase inhibitor targeting mutated EGFR) and bevacizumab (anti-angiogenic targeting VEGF) can have a beneficial therapeutic effect on EGFRmutated tumors. We also show that the addition of afatinib to osimertinib-treated tumors in escape leads to tumor growth inhibition. No such effect is observed with selumetinib or simvastatin. These preclinical mouse models therefore make it possible to test innovative therapeutic combinations and are also a tool of choice for studying resistance mechanisms.  \nIntroduction  \nLung cancer is one of the most common and deadly cancers in Europe and worldwide [ 1] . Of these, nearly 85% are classified as non-small cell lung cancer (NSCLC) with more than 50% of the patients diagnosed at an advanced stage [2] . Current treatments, based mainly on platinum-based chemotherapy, radiotherapy, and surgery, are poorly effective, with a median survival time of no more than 10 months [3] .  \nIn the past two decades, several oncogenic factors have been identified in NSCLC patients, such as EGFR mutations and ALK rearrangements, lea","cbCaieEr6LFjIVuX","https://ap.wps.com/l/cbCaieEr6LFjIVuX","pdf",2683968,18,"English","# Abstract\n# Introduction\n## Non-small cell lung cancer burden and current therapies\n## EGFR mutations and targeted TKI therapies\n## Resistance mechanisms to EGFR TKI and role of osimertinib\n## Rationale for combining bevacizumab with chemotherapy\n#","[{\"question\":\"What models were developed to study non-small cell lung cancer therapies?\",\"answer\":\"The study established luciferase-expressing cell lines from genetic backgrounds typical of pulmonary adenocarcinoma and developed orthotopic preclinical mouse models of NSCLC with very high engraftment efficiency. These models enable monitoring of tumor growth and dissemination in response to treatment.\"},{\"question\":\"How did osimertinib and bevacizumab perform in EGFRmutated tumors?\",\"answer\":\"Concomitant treatment with osimertinib and bevacizumab showed a beneficial therapeutic effect on EGFRmutated tumors in the orthotopic murine models.\"},{\"question\":\"What was the effect of adding afatinib to osimertinib-treated tumors in escape?\",\"answer\":\"Adding afatinib to osimertinib-treated tumors during escape led to tumor growth inhibition. Similar growth inhibition was not observed with selumetinib or simvastatin.\"}]","Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer | PDF",1790041753,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93fdf0bb7386b0ed06dec2ca068dfb69.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52241f7fdc2a4fa210257c6912d16087.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1bf5ea892cde2b8a6e951103ea1317a.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76a41903352b83f84a45f7e786ebb88e.webp",980,1268]